EntryPoint Capital’s Haemonetics HAE Stock Holding History

EntryPoint Capital’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,555	Closed	-$265K	–	762
2025 Q2	$265K	Sell	3,555 -5,981	-63%	-$396K	0.13%	344
2025 Q1	$606K	Buy	9,536 +6,682	+234%	+$454K	0.28%	51
2024 Q4	$223K	Sell	2,854 -3,943	-58%	-$317K	0.09%	544
2024 Q3	$546K	Buy	+6,797	New	+$549K	0.31%	31
2024 Q2	–	Sell	-1,003	Closed	-$85.6K	–	1597
2024 Q1	$85.6K	Buy	+1,003	New	+$78.7K	0.08%	506

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EntryPoint Capital's HAE Position: Q3 2025 in Review

EntryPoint Capital sold out of Haemonetics (HAE) in Q3 2025, closing a stake of 3,555 shares — an estimated $265K sold.

EntryPoint Capital first reported a position in HAE in Q1 2024 and held it in 5 quarters. The position peaked at $606K in Q1 2025. 301 funds tracked by Wall St. Rank hold HAE as of Q3 2025.

EntryPoint Capital reported no remaining Haemonetics position as of Q3 2025 after selling out during the quarter.
EntryPoint Capital sold 3,555 Haemonetics shares in Q3 2025, an estimated $265K.
EntryPoint Capital first reported a position in Haemonetics in Q1 2024 and held it in 5 quarters.
EntryPoint Capital's Haemonetics position peaked at $606K in Q1 2025.
301 funds tracked by Wall St. Rank held Haemonetics as of Q3 2025.

Based on EntryPoint Capital's 13F filing for Q3 2025, filed 13 Nov 2025.